Condition: Solid Tumor Cancer · Sponsor: Sarcoma Oncology Research Center, LLC
This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Erlinda M. Gordon, MD · 3105529999 · egordon@sarcomaoncology.com
Victoria Chua-Alcala, MD · 3105529999 · vchua@sarcomaoncology.com
Always discuss trial participation with your own doctor first.
| Sarcoma Oncology Research Center / Cancer Center of Southern California | Santa Monica, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07671534